Division of Signal Responses, Biosignal Research Center, Kobe University, 1-1 Rokkodai, Nada, Kobe, 657-8501, Japan.
Program of Biomedical Science, Graduate School of Integrated Sciences for Life, Hiroshima University, Hiroshima, 739-8521, Japan.
Sci Rep. 2022 Apr 22;12(1):6622. doi: 10.1038/s41598-022-10528-x.
Parkinson's disease (PD) is the second most common neurodegenerative disease, and diagnostic methods and biomarkers for patients without subjective motor symptoms have not yet been established. Previously, we developed a cytochrome P450 inhibition assay that detects alterations in metabolite levels associated with P450s caused by inflammation and exposure to endogenous or exogenous substances. However, it is unknown whether the P450 inhibition assay can be applied in PD diagnosis. Here, we determined whether the P450 inhibition assay can discriminate sera between patients with PD and healthy individuals. The results of the assay revealed that the P450 inhibition assay can discriminate PD with an area under the receiver operating characteristic curve (AUC) value of 0.814-0.914 in rats and an AUC value of 0.910 in humans. These findings demonstrate that the P450 inhibition assay can aid in the future development of liquid biopsy-based diagnostic methods for PD.
帕金森病（PD）是第二常见的神经退行性疾病，尚未建立用于诊断无主观运动症状患者的方法和生物标志物。此前，我们开发了一种细胞色素 P450 抑制测定法，用于检测与由炎症和接触内源性或外源性物质引起的 P450 相关的代谢物水平的变化。然而，尚不清楚 P450 抑制测定法是否可用于 PD 诊断。在这里，我们确定了 P450 抑制测定法是否可以区分 PD 患者和健康个体的血清。测定结果表明，该 P450 抑制测定法可在大鼠中以 0.814-0.914 的受试者工作特征曲线（ROC）下面积（AUC）值区分 PD，在人类中 AUC 值为 0.910。这些发现表明，P450 抑制测定法可以帮助未来开发基于液体活检的 PD 诊断方法。
